<DOC>
	<DOCNO>NCT00925938</DOCNO>
	<brief_summary>A Phase II , multicenter , double-blind , randomize , placebo-controlled , dose-ranging , study assess efficacy safety 100 , 200 , 400 , 800 , 1200 1600 mcg Misoprostol Vaginal Priming Insert ( MVPI ) Women Requiring Cervical Priming prior in-office hysteroscopy procedure . Each subject randomize receive one vaginal insert . The study drug administer vaginally member clinical research team ( Part I ) insert ( Part II ) 18 - 24 hour prior schedule hysteroscopy clinic visit . The internal o cervix measure baseline , prior hysteroscopy follow visit . The primary outcome measure change diameter internal cervical o baseline ( pre-treatment ) prior hysteroscopy procedure ( post-treatment ) . The hypothesis treatment MVPI soften dilate cervix well placebo .</brief_summary>
	<brief_title>Efficacy Safety Study Misoprostol Vaginal Priming Insert ( MVPI ) Prior Hysteroscopy</brief_title>
	<detailed_description>Prior hysteroscopy procedure , study staff record type procedure conduct desired cervical dilatation . The study drug remove office vaginal examination perform sign irritation trauma . The diameter internal o assess use Hegar dilator . The diameter internal o assess large size Hegar dilator insert internal o without resistance . If subject require dilatation prior procedure , note ; additional dilatation per clinician preference . The use tenaculum allow insertion dilator ( ) / hysteroscope record . The time start end hysteroscopy procedure document . The start time hysteroscopy procedure take time insertion first Hegar dilator completion hysteroscopy procedure . Cervical prim assessment safety record . The subject attend clinic follow-up assessment 7 day procedure . Adverse event concomitant medication record throughout study . The study use adaptive design , begin MVPI 400 mcg escalate reduce dose depend result see particular dose .</detailed_description>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Healthy , premenopausal woman ; Women age 18 year ; Women undergo inoffice procedure require uterine access along cervical dilatation least 5.5 mm ; Women participate Part 1 study : Women least one vaginal delivery least 24 week gestation ; Women Pap smear result require evaluation least one year assess investigator . Note : 1 ) result must Pap smear obtain within one year screening ; 2 ) result unavailable current , Pap smear must obtain result review prior study inclusion ; 3 ) Pap smear perform screening , subject must negative pregnancy test confirm prior Pap smear collection ; Women child bear potential : 1 ) Must negative urine pregnancy test screen prior study drug insertion , take place different day screen visit ; 2 ) Agree use highly effective method birth control ( define low failure rate le 1 % per year ) follow : implant , injectables , combine oral contraceptive , sexual abstinence date subject 's last menstruation completion followup visit , vasectomise partner barrier method ( condom spermicide ) . Women sex relationship need meet criterion confirm possibility pregnancy ; Women agree refrain vaginal intercourse study drug place ; Women agree refrain use follow day study drug insertion completion followup visit : feminine deodorant sprays/products , spermicides* , douche , condoms* , tampon , diaphragms pharmaceutical counter vaginal product . Barrier method contraception indicate ( * ) may resume follow dilatation procedure ; Women provide write informed consent . Menopausal woman ; Women menstrual period last &gt; 10 day duration ; Baseline internal cervical o ≥ 3 mm ; Women prior endometrial ablation ; Women breastfeed ; History current diagnosis glaucoma ; Women clinically significant vaginal cervical abnormality ( e.g . symptom infection ) would interfere conduct study procedure prior study drug insertion ; Women currently undergo treatment cancer ( basal cell carcinoma acceptable ) ; Body Mass Index ( BMI ) ≥ 50 ; Women participate Part 1 study : Women history loop electrosurgical excision procedure ( LEEP ) cold knife conization without intervene vaginal delivery ; Women intrauterine device ( IUD ) place , IUD remove within 30 day screen visit schedule IUD insert hysteroscopy procedure ; Women use NuvaRing® contraception ; Known suspect allergy misoprostol , prostaglandins excipients ; Unable comply protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hysteroscopy</keyword>
	<keyword>Cervical priming</keyword>
	<keyword>Cervical dilatation</keyword>
	<keyword>Misoprostol</keyword>
	<keyword>Endoscopy , uterine</keyword>
</DOC>